Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma

Molecular Neurobiology

Volumn 55, Issue 9, 2018, Pages 7242-7258

  Souza, Bárbara Kunzler ^a,b   da Costa Lopez, Patrícia Luciana ^c   Menegotto, Pâmela Rossi ^a,b   Vieira, Igor Araujo ^a   Kersting, Nathalia ^a   Abujamra, Ana Lúcia ^a,d   Brunetto, André T ^a,d   Brunetto, Algemir L ^a,d   Gregianin, Lauro ^a,c   de Farias, Caroline Brunetto ^a,d   Thiele, Carol J ^e   Roesler, Rafael ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Children s Cancer Institute   (Brazil)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epigenetics; Ewing sarcoma; Histone deacetylase; Neural differentiation; Pediatric cancer

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MYC PROTEIN; UNCLASSIFIED DRUG; EWS-FLI FUSION PROTEIN; ONCOPROTEIN; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR FLI 1;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD CANCER; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; EWING SARCOMA; EWING SARCOMA CELL LINE; EWS FLI1 GENE; FUSION GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; ONCOGENE; PERCENTAGE OF CELLS IN G0/G1 PHASE; PROTEIN EXPRESSION LEVEL; RD ES 1 CELL LINE; SARCOMA CELL; SIGNAL TRANSDUCTION; SK-ES-1 CELL LINE; CELL CYCLE CHECKPOINT; CELL DIFFERENTIATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; NERVE CELL; PATHOLOGY; TUMOR CELL LINE;

BUTYRIC ACID; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEURONS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; SPHEROIDS, CELLULAR; TRANSCRIPTION, GENETIC;

EID: 85045141479     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-018-0874-6     Document Type: Article

References (63)

1. Balamuth NJ, Womer RB (2010) Ewing’s sarcoma. Lancet Oncol 11(2):184–192. 10.1016/S1470-2045(09)70286-4
2. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33(27):3036–3046. 10.1200/JCO.2014.59.5256
3. Ross KA, Smyth NA, Murawski CD, Kennedy JG (2013) The biology of Ewing sarcoma. ISRN Oncol 2013:759725. 10.1155/2013/759725
4. Cavazzana AO, Miser JS, Jefferson J, Triche TJ (1987) Experimental evidence for a neural origin of Ewing’s sarcoma of bone. Am J Pathol 127(3):507–518
5. Parham DM, Hijazi Y, Steinberg SM, Meyer WH, Horowitz M, Tzen CY, Wexler LH, Tsokos M (1999) Neuroectodermal differentiation in Ewing’s sarcoma family of tumors does not predict tumor behavior. Hum Pathol 30(8):911–918. 10.1016/S0046-8177(99)90244-7
6. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D, Burdach SE (2004) DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64(22):8213–8221. 10.1158/0008-5472.CAN-03-4059
7. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A, Hsu JH, Lawlor ER (2011) Modeling initiation of Ewing sarcoma in human neural crest cells. PLoS One 6:1–10
8. Miyagawa Y, Okita H, Nakaijima H, Horiuchi Y, Sato B, Taguchi T, Toyoda M, Katagiri YU et al (2008) Inducible expression of chimeric EWS/ETS proteins confers Ewing’s family tumor-like phenotypes to human mesenchymal progenitor cells. Mol Cell Biol 28(7):2125–2137. 10.1128/MCB.00740-07
9. Riggi N, Cironi L, Provero P, Suvà ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A et al (2005) Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65(24):11459–11468. 10.1158/0008-5472.CAN-05-1696
10. Riggi N, Suvà ML, Suvà D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC et al (2008) EWS-FLI-1 expression triggers a Ewing’s sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68(7):2176–2185. 10.1158/0008-5472.CAN-07-1761
11. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O (2007) Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11(5):421–429. 10.1016/j.ccr.2007.02.027
12. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR (2013) Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell 23(2):215–227. 10.1016/j.ccr.2012.12.019
13. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL et al (2014) The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 4(11):1326–1341. 10.1158/2159-8290.CD-13-1037
14. Lawlor ER, Thiele CJ (2012) Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res 18(10):2768–2779. 10.1158/1078-0432.CCR-11-1921
15. Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE et al (2014) EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 26(5):668–681. 10.1016/j.ccell.2014.10.004
16. Sheffield NC, Pierron G, Klughammer J, Datlinger P, Schönegger A, Schuster M, Hadler J, Surdez D et al (2017) DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med 23(3):386–395. 10.1038/nm.4273
17. Gomez NC, Hepperla AJ, Dumitru R, Simon JM, Fang F, Davis IJ (2016) Widespread chromatin accessibility at repetitive elements links stem cells with human cancer. Cell Rep 17(6):1607–1620. 10.1016/j.celrep.2016.10.011
18. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705. 10.1016/j.cell.2007.02.005
19. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784. 10.1038/nrd2133
20. Mottamal M, Zheng S, Huang TL, Wang G (2015) Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20(3):3898–3941. 10.3390/molecules20033898
21. Candido EPM, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14(1):105–113. 10.1016/0092-8674(78)90305-7
22. dos Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL (2014) In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol Rep 31(2):955–968. 10.3892/or.2013.2907
23. Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, Wardelmann E, Frühwald MC et al (2015) Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines. Anti-Cancer Drugs 26(8):843–851. 10.1097/CAD.0000000000000256
24. Sonnemann J, Dreyer L, Hartwig M, Palani CD, le Hong TT, Klier U, Bröker B, Völker U et al (2007) Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. J Cancer Res Clin Oncol 133(11):847–858. 10.1007/s00432-007-0227-8
25. Silva AO, Felipe KB, Villodre ES, Lopez PLC, Lenz G (2016) A guide for the analysis of long-term population growth in cancer. Tumour Biol 37(10):13743–13749. 10.1007/s13277-016-5255-z
26. Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J et al (2014) Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. Oncol Rep 32(2):845–852. 10.3892/or.2014.3269
27. Suvà ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suvà D, Clément V et al (2009) Identification of cancer stem cells in Ewing’s sarcoma. Cancer Res 69(5):1776–1781. 10.1158/0008-5472.CAN-08-2242
28. Pastrana E, Silva-Vargas V, Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8(5):486–498. 10.1016/j.stem.2011.04.007
29. Barnard JA, Warwick G (1993) Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ 4(6):495–501
30. Archer SY, Meng S, Shei A, Hodin RA (1998) p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 95(12):6791–6796. 10.1073/pnas.95.12.6791
31. Jiang W, Guo Q, Wu J, Guo B, Wang Y, Zhao S, Lou H, Yu X et al (2012) Dual effects of sodium butyrate on hepatocellular carcinoma cells. Mol Biol Rep 39(5):6235–6242. 10.1007/s11033-011-1443-5
32. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L et al (2014) The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 10(7):e1004475. 10.1371/journal.pgen.1004475
33. Sakimura R, Tanaka K, Nakatani F, Matsunobu T, Li X, Hanada M, Okada T, Nakamura T et al (2005) Antitumor effects of histone deacetylase inhibitor on Ewing’s family tumors. Int J Cancer 116(5):784–792. 10.1002/ijc.21069
34. Hunter T, Pines J (1994) Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 79(4):573–582. 10.1016/0092-8674(94)90543-6
35. Zhang J, Hu S, Schofield DE, Sorensen PHB, Triche TJ (2004) Selective usage of D-type cyclins by Ewing’s tumors and rhabdomyosarcomas. Cancer Res 64(17):6026–6034. 10.1158/0008-5472.CAN-03-2594
36. Lorenz V, Hessenkemper W, Rödiger J, Kyrylenko S, Kraft F, Baniahmad A (2011) Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells. Horm Mol Biol Clin Investig 7(1):265–272. 10.1515/HMBCI.2011.020
37. WS X, Perez G, Ngo L, Gui CY, Marks PA (2005) Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65:7832–7839
38. Thiele CJ, Li Z, McKee AE (2009) On Trk—the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 15(19):5962–5967. 10.1158/1078-0432.CCR-08-0651
39. Heinen TE, Dos Santos RP, da Rocha A, Dos Santos MP, Lopez PL, Silva Filho MA, Souza BK, Rivero LF et al (2016) Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma. Oncotarget 7(23):34860–34880. 10.18632/oncotarget.8992
40. Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc B Biol Sci 361(1473):1545–1564. 10.1098/rstb.2006.1894
41. Hans F, Dimitrov S (2001) Histone H3 phosphorylation and cell division. Oncogene 20(24):3021–3027. 10.1038/sj.onc.1204326
42. Strelkov IS, Davie JR (2002) Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Res 62(1):75–78
43. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y et al (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/aurora-B overexpression contributes to chromosome number instability. Cancer Res 62(18):5168–5177
44. Espino PS, Pritchard S, Heng HH, Davie JR (2009) Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. Int J Cancer 124(3):562–567. 10.1002/ijc.23959
45. Simboeck E, Sawicka A, Zupkovitz G, Senese S, Winter S, Dequiedt F, Ogris E, Di Croce L et al (2010) A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 285(52):41062–41073. 10.1074/jbc.M110.184481
46. Shukla S, Meeran SM (2014) Epigenetics of cancer stem cells: pathways and therapeutics. Biochim Biophys Acta 1840(12):3494–3502. 10.1016/j.bbagen.2014.09.017
47. Sankar S, Bell R, Stephens B, Zhuo R, Sharma S, Bearss DJ, Lessnick SL (2013) Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. Oncogene 32(42):5089–5100. 10.1038/onc.2012.525
48. Svoboda LK, Harris A, Bailey NJ, Schwentner R, Tomazou E, von Levetzow C, Magnuson B, Ljungman M et al (2014) Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs. Epigenetics 9(12):1613–1625. 10.4161/15592294.2014.988048
49. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA (2008) The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 27(23):3282–3291. 10.1038/sj.onc.1210991
50. Karantzali E, Schulz H, Hummel O, Hubner N, Hatzopoulos A, Kretsovali A (2008) Histone deacetylase inhibition accelerates the early events of stem cell differentiation: transcriptomic and epigenetic analysis. Genome Biol 9(4):R65. 10.1186/gb-2008-9-4-r65
51. Yang HK, Sundholm-Peters NL, Goings GE, Walker AS, Hyland K, Szele FG (2004) Distribution of doublecortin expressing cells near the lateral ventricles in the adult mouse brain. J Neurosci Res 76(3):282–295. 10.1002/jnr.20071
52. Rocchi A, Manara M (2010) CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest 120(3):668–680. 10.1172/JCI36667
53. Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP et al (2016) CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-notch-mediated control of NF-κB signaling. Oncogene 35(30):3944–3954. 10.1038/onc.2015.463
54. Chopin V, Lagadec C, Toillon RA, Le Bourhis X (2016) Neurotrophin signaling in cancer stem cells. Cell Mol Life Sci 73(9):1859–1870. 10.1007/s00018-016-2156-7
55. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, Falck JR, Peng J et al (2007) Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 6(5):812–819. 10.1074/mcp.M700021-MCP200
56. Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M (2014) The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol 15(8):536–550. 10.1038/nrm3841
57. Goudarzi A, Zhang D, Huang H, Barral S, Kwon OK, Qi S, Tang Z, Buchou T et al (2016) Dynamic competing histone H4 K5K8 acetylation and butyrylation are hallmarks of highly active gene promoters. Mol Cell 62(2):169–180. 10.1016/j.molcel.2016.03.014
58. Xu G, Wang J, Wu Z, Qian L, Dai L, Wan X, Tan M, Zhao Y et al (2014) SAHA regulates histone acetylation, butyrylation, and protein expression in neuroblastoma. J Proteome Res 13(10):4211–4219. 10.1021/pr500497e
59. Prasad KN, Sinha PK (1976) Effect of sodium butyrate on mammalian cells in culture: a review. In Vitro 12: 125–132
60. Rivero JA, Adunyah SE (1996) Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem Biophys Res Commun 224(3):796–801. 10.1006/bbrc.1996.1102
61. Rivero JA, Adunyah SE (1998) Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem Biophys Res Commun 248(3):664–668. 10.1006/bbrc.1998.9041
62. Nör C, Sassi FA, de Farias CB, Schwartsmann G, Abujamra AL, Lenz G, Brunetto AL, Roesler R (2013) The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells. Mol Neurobiol 48(3):533–543. 10.1007/s12035-013-8441-7
63. Almeida VR, Vieira IA, Buendia M, Brunetto AT, Gregianin LJ, Brunetto AL, Klamt F, de Farias CB et al (2017) Combined treatments with a retinoid receptor agonist and epigenetic modulators in human neuroblastoma cells. Mol Neurobiol 54(10):7610–7619. 10.1007/s12035-016-0250-3